IMVT-1402 meets Phase 2 RA goals, plans FDA talks
Immunovant's IMVT-1402 advanced in rheumatoid arthritis trials, driving positive sentiment as the company prepares regulatory discussions. The firm also indicated it will halt development in Sjogren's disease.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed